The broad phosphodiesterase inhibition raises questions about the compound's safety and potential side effects. Clinical trials and further studies would be necessary to assess the compound's safety profile, its therapeutic window, and the extent to which off-target effects are clinically significant.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
6-((6-(3,4-difluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-methyl)quinoline
7-bromo-N-[(1-oxyl-4-bromo-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl]-9H-fluoren-2-amine radical
C23H26N2O7
Glyoxylic acid
3-(phenylthio)-2,3-dihydrothiophene 1,1-dioxide
